Assertio Holdings (ASRT) Change in Receivables (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Change in Receivables came in at -$58.6 million in Q1 2026, down 581.29% year-on-year from $12.2 million in Q1 2025, and down 176.37% quarter-over-quarter from -$21.2 million in Q4 2025.
Assertio Holdings (ASRT) Change in Receivables (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Change in Receivables across 8 years of filings, most recently posting -$58.6 million for Q1 2026.
- Change in Receivables for Q1 2026 came in at -$58.6 million, down 581.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.8 million (down 120.12% YoY), and the FY2025 annual result was $66.0 million, up 921.99% from the prior year.
- Change in Receivables came in at -$58.6 million for Q1 2026 at Assertio Holdings, down from -$21.2 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $80.2 million in Q3 2025 to a low of -$58.6 million in Q1 2026.
- The 5-year median for Change in Receivables is -$2.7 million (2024), against an average of -$2.0 million.
- Across the five-year window, Change in Receivables slumped 2286.71% in 2023 and jumped 1494.45% in 2025, its largest moves.
- Assertio Holdings' Change in Receivables stood at $677000.0 in 2022, then plunged by 2286.71% to -$14.8 million in 2023, then jumped by 161.98% to $9.2 million in 2024, then sank by 331.0% to -$21.2 million in 2025, then sank by 176.37% to -$58.6 million in 2026.
- The last three Change in Receivables figures came in at -$58.6 million (Q1 2026), -$21.2 million (Q4 2025), and $80.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -78.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 106.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -38.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 81.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 23.22 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 116.25 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.23 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | -58.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.58 Mn |
| Mar 31, 2026 | -58.58 Mn |
| Dec 31, 2025 | -21.20 Mn |
| Dec 31, 2025 | -21.20 Mn |
| Sep 30, 2025 | 80.22 Mn |
| Sep 30, 2025 | 80.22 Mn |
| Jun 30, 2025 | -5.20 Mn |
| Jun 30, 2025 | -5.20 Mn |
| Mar 31, 2025 | 12.17 Mn |
| Mar 31, 2025 | 12.17 Mn |
| Dec 31, 2024 | 9.18 Mn |
| Dec 31, 2024 | 9.18 Mn |
| Sep 30, 2024 | 5.03 Mn |
| Sep 30, 2024 | 5.03 Mn |
| Jun 30, 2024 | -2.70 Mn |
| Jun 30, 2024 | -2.70 Mn |
| Mar 31, 2024 | -5.05 Mn |
| Mar 31, 2024 | -5.05 Mn |
| Dec 31, 2023 | -14.80 Mn |
| Dec 31, 2023 | -14.80 Mn |